Patents Examined by Lorraine Spector
  • Cytokine receptor zcytor19
    Patent number: 7601809
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: October 13, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Scott R. Presnell, Wenfeng Xu, Julia E. Novak, Theodore E. Whitmore, Francis J. Grant
  • Human anti-epidermal growth factor receptor antibody
    Patent number: 7598350
    Abstract: The present invention provides a fully human antibody that binds human EGFR with affinity comparable to or higher than IMC-C225, and that neutralizes activation of EGFR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chains antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells and animals that encode and express these antibodies. The invention further provides a method for neutralizing activation of EGFR, treating in a mammal with neoplastic growth and non-cancerous hyperproliferative diseases using the antibodies alone or in combination with other agents.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: October 6, 2009
    Assignee: ImClone LLC
    Inventors: Meilin Liu, Zhenping Zhu
  • Hedgehog interacting proteins and uses related thereto
    Patent number: 7585671
    Abstract: The present invention concerns the discovery of a new family of hedgehog binding proteins, referred to herein as “hedgehog interacting proteins” or “HIPs”, which are demonstrated to bind to hedgehog polypeptides with high affinity. As described herein, the vertebrate HIP proteins exhibit spatially and temporally restricted expression domains indicative of important roles in hedgehog-mediated induction.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: September 8, 2009
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew P. McMahon, Pao-Tien Chuang
  • Stable pharmaceutical composition granulocyte-colony stimulating factor
    Patent number: 7585496
    Abstract: The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF).
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: September 8, 2009
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Barbara Podobnik, Vladka Gaberc Porekar, Viktor Menart
  • Antibody to TNF receptor-like molecules
    Patent number: 7569387
    Abstract: Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: August 4, 2009
    Assignee: Amgen Inc.
    Inventors: Lars Eyde Theill, Richard Yeh, Scott Michael Silbiger, Gang Yu, Giorgio Senaldi
  • Method for identifying modulators of the dioxin/aryl hydrocarbon receptor (AHR)
    Patent number: 7569352
    Abstract: Agents useful for modulating the dioxin/aryl hydrocarbon receptor (AhR) can now be identified by determining the binding to said receptor and whether said agent suppresses or inhibits the expression of a gene substantially consisting of a sequence according to one of SEQ. ID. NO. 1 and SEQ. ID. NO. 2; a nucleotide sequence functionally homologous, or substantially homologous, or at least 90% identical to one of SEQ. ID. NO. 1 and SEQ. ID. NO. 2; and a nucleotide sequence complementary to the nucleotide sequence of SEQ. ID. NO. 1 or SEQ. ID. NO. 2. Such agents find utility in pharmaceutical compositions and methods for the prevention, alleviation or treatment of diseases involving gastrointestinal hyperplasia, such as gastrointestinal cancer or gastric cancer.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: August 4, 2009
    Assignee: InDex Pharmaceuticals AB
    Inventors: Petra Von Stein, Patrik Andersson, Nikolai Kouznetsov, Lorenz Poellinger
  • E6AP-binding proteins
    Patent number: 7566455
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly human cells, of novel protein-protein interactions between certain cellular proteins, referred to herein as “E6AP-binding proteins” or “E6AP-BPs”, and the cellular protein E6AP, the latter of which is a component of a ubiquitin-ligase (E3) enzyme. The association of E6AP and the subject E6AP-binding proteins implicates the E6AP-binding proteins in a number of basic cellular functions, such as regulation of gene expression, regulation of the cell-cycle, modification of cell surface receptors, biogenesis of ribosomes, and DNA repair. One of the E6AP-binding proteins shares certain homology with the papillomavirus E6 protein, which also binds E6AP.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 28, 2009
    Assignee: GPC Biotech, Inc.
    Inventors: Peggy L. Beer-Romero, Giulio Draetta, Mark Rolfe
  • Method of treatment of an infection in an animal with GM-CSF cysteine muteins in the proximal region to helix A
    Patent number: 7560101
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 14, 2009
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, III, Daniel J. Doherty
  • Compositions for regulation of tumor necrosis factor-alpha
    Patent number: 7560265
    Abstract: The present invention relates to compositions relating a nucleic acid encoding an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides vectors for expressing proteins useful for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: July 14, 2009
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Soo-Hyun Kim, Charles A. Dinarello, Tania Azam
  • Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
    Patent number: 7557195
    Abstract: The present invention relates to a conjugate of a biocompatible polymer and a G-CSF bonded through a thiol group of a dysteine residue in G-CSF at a 1:1 molar ratio, and methods of preparation thereof.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: July 7, 2009
    Assignee: Biopolymed, Inc.
    Inventor: Myung-Ok Park
  • Pharmaceutical compositions containing angiogenic activators
    Patent number: 7553492
    Abstract: The invention relates to therapeutic compositions used in the field of angiogenesis, comprising nucleotide sequences of genes, the involvement of said genes in the angiogenesis mechanism having been demonstrated by the Applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against said polypeptide sequences. The invention also relates to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing said cells, which are used to treat angiogenic disorders. Moreover, the invention relates to methods of diagnosing and/or prognosticating antigenic disorders and to novel methods of screening active compounds in the treatment of said disorders.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: June 30, 2009
    Assignee: Gene Signal
    Inventors: Salman Al-Mahmood, Sylvie Colin, Christophe Schneider
  • Antibody to the human OX40 receptor
    Patent number: 7550140
    Abstract: The present invention provides binding molecules, such as human binding molecules, that bind to and stimulate the human OX40-receptor. The invention also provides nucleic acids encoding such binding molecules. Methods for producing such binding molecules are also provided by the present invention. The binding molecules and nucleic acids are useful in the stimulation of human T-cells and can be used to enhance antigen-specific immune responses.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: June 23, 2009
    Assignee: Crucell Holland B.V.
    Inventors: Alexander Berthold Hendrik Bakker, Pauline Marie Louise Meester-Rood, Adrianus Quirinus Bakker
  • Thrombopoietin proteins with improved properties
    Patent number: 7541439
    Abstract: The invention concerns human thrombopoietin and in particular modified forms of thrombopoietin (TPO) with improved properties. The improved proteins contain amino acid substitutions at specific positions within the TPO molecule. The invention provides modified TPO molecules, preferably fusion proteins comprising immunoglobulin constant regions and modified human TPO, with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: June 2, 2009
    Assignee: Merck Patent GmbH
    Inventors: Matthew Baker, John Watkins
  • Chimeric molecule for the treatment of th2-like cytokine mediated disorders
    Patent number: 7541040
    Abstract: The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: June 2, 2009
    Assignees: The United States of America as represented by the Department of Health and Human Serivces, The Regents of the University of Michigan, Office of Technology Transfer
    Inventors: Raj K. Puri, Cory M. Hogaboam, Claudia Jakubzick, Steven L. Kunkel
  • Monoclonal antibodies recognizing BAG3 protein sequences and their use in diagnostic and therapy of cell death-involving diseases
    Patent number: 7537760
    Abstract: The present invention provides BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for modulation of cell survival and/or death, in particular in leukemias, other neoplasias and apoptosis-involving diseases. More particularly the invention refers to the use of specific antisense-based constructs and peptide-specific polyclonal and monoclonal antibodies in leukemias, other neoplasias and cell death-involving diseases.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: May 26, 2009
    Inventors: Arturo Leone, Maria Caterina Turco
  • Antibodies that bind purified mammalian FLT3 ligands
    Patent number: 7537932
    Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 26, 2009
    Assignees: Schering Corporation, Inserm
    Inventors: Charles H. Hannum, Janice A. Culpepper, Frank D. Lee, Daniel Birnbaum
  • Purified mammalian Flt3 ligands; agonists; antagonists
    Patent number: 7534867
    Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 19, 2009
    Assignees: Schering Corporation, Inserm
    Inventors: Charles H. Hannum, Janice A. Culpepper, Frank D. Lee, Daniel Birnbaum
  • Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
    Patent number: 7514239
    Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: April 7, 2009
    Assignee: Amgen Inc.
    Inventors: Christopher J. R. Paszty, Jin Cao, Dimitry M. Danilenko, Jianhua Gong, David C. Hill
  • Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
    Patent number: 7511016
    Abstract: The present invention provides methods and compositions for the treatment, diagnosis, and prevention of diseases, such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods include the administration of pharmaceutical complexes comprising annexins coupled to pharmaceutical compounds or carriers to subjects. The present invention also provides methods and compositions for delivering therapeutic compounds into the diseased cells of a subject either to kill them, such as tumor cells, or to rescue them, such as cardiomyocytes and neurons. The compositions include annexins, annexin variants, derivatives thereof, and complexes thereof.
    Type: Grant
    Filed: July 7, 2004
    Date of Patent: March 31, 2009
    Assignee: MosaMedix B.V.
    Inventor: Chris Reutelingsperger
  • Nucleic acids encoding rat hyaluronan receptor for endocytosis
    Patent number: 7507556
    Abstract: A purified nucleic acid segment encoding a functionally active hyaluronan receptor for endocytosis (HARE) or an active peptide fragment thereof, and methods for producing functionally active HARE or an active peptide fragment thereof therefrom, wherein the functionally active HARE or an active peptide fragment thereof is able to specifically bind HA, chondroitin and chondroitin sulfate.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: March 24, 2009
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Paul H. Weigel, Janet Weigel, Bin Zhou